Abstract Objectives: The incidence of cerebellar Glioblastoma Multiforme (cGBM) is rare. Database like TCGA have not distinguish cGBM from GBM, our knowledge on cGBM gene expression characteristics is limited. The expression status of Oligodendrocyte Lineage Transcription factor 2 (OLIG2) and its clinical significance in cGBM is still unclear. Methods: The clinical data and tissue specimens of 73 cGBM patients were retrospectively studied. The association between OLIG2 expression level and the demographic characteristics of cGBM patients was identified by the Chi-Square test. The survival curves were drawn by Kaplan-Meier analysis. The independent prognostic factors was calculated according to Cox regression analysis. Results: The OLIG2 high expression was observed in about 57.5% (42/73) of the cGBM patients. Patients with high OLIG2 expression levels had a higher alive ratio at the end of follow-up (alive ratio: 70.6% vs. 29.4%, p = 0.04). The median survival time was 21 months and 13 months for high and low expression of OLIG2 (p < 0 .05). Univariate analysis and Multivariate analysis indicated that EOR (HR = 3.89, 95% CI 1.23−12.26, p = 0.02), low OLIG2 expression (HR = 5.26, 95% CI 1.13−24.59, p = 0.04), and without adjuvant therapy (HR = 4.95, 95% CI 1.22−20.00, p = 0.03) were independent risk factors for the OS of cGBM patients. Conclusion: High expression level of OLIG2 could be used as an independent favorable prognosis indicator in cGBM patients and be recognized as a characteristic biomarker of cGBM. Objectives (cGBM rare GBM limited OLIG (OLIG2 unclear Methods 7 studied ChiSquare Chi Square test KaplanMeier Kaplan Meier Results 575 57 5 57.5 42/73 4273 42 (42/73 followup follow up 706 70 6 70.6 vs 294 29 4 29.4% 0.04. 004 0.04 . 04 0.04) 1 .05. 05 .05 .05) HR 389 3 89 3.89 95 1231226 23 12 26 1.23−12.26 0.02, 002 0.02 , 02 0.02) 526 5.26 1132459 24 59 1.13−24.59 0.04, 495 4.95 1222000 22 20 00 1.22−20.00 0.03 003 03 Conclusion (OLIG 57. 42/7 427 (42/7 70. 29.4 0.0 .0 38 8 3.8 9 123122 1.23−12.2 52 5.2 113245 1.13−24.5 49 4.9 122200 1.22−20.0 42/ (42/ 29. 0. 3. 12312 1.23−12. 5. 11324 1.13−24. 4. 12220 1.22−20. (42 1231 1.23−12 1132 1.13−24 1222 1.22−20 (4 123 1.23−1 113 1.13−2 122 1.22−2 ( 1.23− 11 1.13− 1.22− 1.23 1.13 1.22 1.2 1.1 1.

Six of the 15 species of venomous snakes found in Taiwan are responsible for most of the clinically significant envenomations in the country. These species are: Trimeresurus mucrosquamatus, Trimeresurus stejnegeri, Naja atra, Bungarus multicinctus, Deinagkistrodon acutus and Daboia russelii siamensis, which together can be subdivided into three groups based on their venom effects. Primary treatment consists of rapid administration of appropriate antivenoms. The present study aimed to identify a proper dose of antivenom for each snake group as well as to describe hemorrhagic, neurotoxic, and mixed effects of their venoms. A retrospective chart review identified 72 snakebite cases referred to an emergency department. Data on epidemiology, examination findings, snake identification, treatment, antivenom dose and complications were collected. After excluding 14 patients, data from 58 victims were analyzed. Most studied cases were male (86%). Significantly higher doses of antivenom were administered against neurotoxic envenomations (mean dose: three vials) compared with the other two (p < 0.05). Moreover, patients affected by neurotoxic bites were more likely to develop blurred vision and other complications (p < 0.05). Multivariate logistic regression analysis indicated that neurotoxic envenomation was a risk factor for complications (OR: 8.84, 95% CI: 1.06-73.73). Neurotoxic envenomations and complication occurrence were positively correlated with antivenom dosage. In conclusion, patients affected by neurotoxic envenomations received higher doses of antivenom than others whereas incidence of complications was associated with higher antivenom doses.